Cargando…

A Pilot Retrospective Study Validating Noncommunicable Disease Risk Assessment Score (AMNRAS)

BACKGROUND: Globally Noncommunicable Diseases is lead causes of mortality. This calls for the need of sensitive and cost appropriate screening tools to identify asymptomatic healthy individuals with higher risk and/or subclinical NCD in the community. The study aims to generate pilot evidence based,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Arti, Sathiyanarayanan, S, Aravindakshan, Rajeev, Kakkar, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631129/
https://www.ncbi.nlm.nih.gov/pubmed/34912510
http://dx.doi.org/10.4103/ijpvm.IJPVM_206_19
_version_ 1784607491359768576
author Gupta, Arti
Sathiyanarayanan, S
Aravindakshan, Rajeev
Kakkar, Rakesh
author_facet Gupta, Arti
Sathiyanarayanan, S
Aravindakshan, Rajeev
Kakkar, Rakesh
author_sort Gupta, Arti
collection PubMed
description BACKGROUND: Globally Noncommunicable Diseases is lead causes of mortality. This calls for the need of sensitive and cost appropriate screening tools to identify asymptomatic healthy individuals with higher risk and/or subclinical NCD in the community. The study aims to generate pilot evidence based, validated, good quality, cost appropriate, and sustainable risk assessment score for NCD for developing countries like India. METHODS: This descriptive retrospective study of diabetic camp data of 84 patients was conducted. A risk score having 10 questions and three measurements for NCDs appropriate for Indian communities was generated. It was compared to IDRS, FINDRISC, FRS, CBAC, and WHO/ISH prediction charts. RESULTS: The study finally included 36 patients with NCD as case and 44 subjects without NCD as control. The means of weight, waist circumference, blood pressure, and blood sugar were significantly different among the two groups. AMNRAS of more than 14 was highly predictive for an individual to be at risk of NCD or sub clinical case of NCD requiring evaluation. The proposed cut-off of 8 for AMNRAS, the sensitivity and NPV was highest compared to other score, 88.9% and 84.6%, respectively. Score for the Area under curve was significantly higher for AMNRAS [0.83 (0.74 to 0.92)] compared to other scores. CONCLUSIONS: AMNRAS has higher performance parameters than the other five tested in the present study. Other scoring system performs only modestly in discrimination of NCD cases. The accuracy of AMNRAS for NCD risk will have to be determined in large size cohorts.
format Online
Article
Text
id pubmed-8631129
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-86311292021-12-14 A Pilot Retrospective Study Validating Noncommunicable Disease Risk Assessment Score (AMNRAS) Gupta, Arti Sathiyanarayanan, S Aravindakshan, Rajeev Kakkar, Rakesh Int J Prev Med Original Article BACKGROUND: Globally Noncommunicable Diseases is lead causes of mortality. This calls for the need of sensitive and cost appropriate screening tools to identify asymptomatic healthy individuals with higher risk and/or subclinical NCD in the community. The study aims to generate pilot evidence based, validated, good quality, cost appropriate, and sustainable risk assessment score for NCD for developing countries like India. METHODS: This descriptive retrospective study of diabetic camp data of 84 patients was conducted. A risk score having 10 questions and three measurements for NCDs appropriate for Indian communities was generated. It was compared to IDRS, FINDRISC, FRS, CBAC, and WHO/ISH prediction charts. RESULTS: The study finally included 36 patients with NCD as case and 44 subjects without NCD as control. The means of weight, waist circumference, blood pressure, and blood sugar were significantly different among the two groups. AMNRAS of more than 14 was highly predictive for an individual to be at risk of NCD or sub clinical case of NCD requiring evaluation. The proposed cut-off of 8 for AMNRAS, the sensitivity and NPV was highest compared to other score, 88.9% and 84.6%, respectively. Score for the Area under curve was significantly higher for AMNRAS [0.83 (0.74 to 0.92)] compared to other scores. CONCLUSIONS: AMNRAS has higher performance parameters than the other five tested in the present study. Other scoring system performs only modestly in discrimination of NCD cases. The accuracy of AMNRAS for NCD risk will have to be determined in large size cohorts. Wolters Kluwer - Medknow 2021-10-19 /pmc/articles/PMC8631129/ /pubmed/34912510 http://dx.doi.org/10.4103/ijpvm.IJPVM_206_19 Text en Copyright: © 2021 International Journal of Preventive Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Gupta, Arti
Sathiyanarayanan, S
Aravindakshan, Rajeev
Kakkar, Rakesh
A Pilot Retrospective Study Validating Noncommunicable Disease Risk Assessment Score (AMNRAS)
title A Pilot Retrospective Study Validating Noncommunicable Disease Risk Assessment Score (AMNRAS)
title_full A Pilot Retrospective Study Validating Noncommunicable Disease Risk Assessment Score (AMNRAS)
title_fullStr A Pilot Retrospective Study Validating Noncommunicable Disease Risk Assessment Score (AMNRAS)
title_full_unstemmed A Pilot Retrospective Study Validating Noncommunicable Disease Risk Assessment Score (AMNRAS)
title_short A Pilot Retrospective Study Validating Noncommunicable Disease Risk Assessment Score (AMNRAS)
title_sort pilot retrospective study validating noncommunicable disease risk assessment score (amnras)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631129/
https://www.ncbi.nlm.nih.gov/pubmed/34912510
http://dx.doi.org/10.4103/ijpvm.IJPVM_206_19
work_keys_str_mv AT guptaarti apilotretrospectivestudyvalidatingnoncommunicablediseaseriskassessmentscoreamnras
AT sathiyanarayanans apilotretrospectivestudyvalidatingnoncommunicablediseaseriskassessmentscoreamnras
AT aravindakshanrajeev apilotretrospectivestudyvalidatingnoncommunicablediseaseriskassessmentscoreamnras
AT kakkarrakesh apilotretrospectivestudyvalidatingnoncommunicablediseaseriskassessmentscoreamnras
AT guptaarti pilotretrospectivestudyvalidatingnoncommunicablediseaseriskassessmentscoreamnras
AT sathiyanarayanans pilotretrospectivestudyvalidatingnoncommunicablediseaseriskassessmentscoreamnras
AT aravindakshanrajeev pilotretrospectivestudyvalidatingnoncommunicablediseaseriskassessmentscoreamnras
AT kakkarrakesh pilotretrospectivestudyvalidatingnoncommunicablediseaseriskassessmentscoreamnras